Compare EPAM Systems Inc (EPAM) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPAM Systems Inc vs Merck & Co., Inc. — how do they compare? EPAM Systems Inc trades at $113.92 (market cap $5.87B), while Merck & Co., Inc. trades at $145.85 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 59.8× EPAM Systems Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while EPAM Systems Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold EPAM Systems Inc for 37 Days and Merck & Co., Inc. for 98 Days on average.
| EPAM | MRK | |
|---|---|---|
Market Cap | $5.87B | $351.28B |
Volume | 847,420 | 7,969,665 |
Sector | Technology | Health |
52-Week High | $221.40 | $156.43 |
52-Week Low | $76.04 | $82.49 |
Typical Hold Time | 37 Days | 98 Days |
Enterprise Value | $5.24B | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPAM Systems trades at $114.00, up 5.24% today, with a bearish technical signal but strong fundamentals. Recent earnings have consistently beaten estimates, with Q2 2026 EPS of $3.38 surpassing the $3.16 expectation. Revenue grew to $5.46 billion in 2025, though net income margin compressed to 6.92%. The company maintains solid cash flow from operations of $654.93 million and a healthy balance sheet with $1.29 billion in cash.
The outlook is mixed; analyst consensus is a Buy with a $119.00 price target, but near-term revenue headwinds and AI disruption risks persist. Investment opportunity lies in attractive valuation multiples (P/E 15.45, EV/EBITDA 7.25) and potential share repurchases urged by activists. Key risks include slower North American growth and competitive pressures in digital transformation services.
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
